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Abstract
Background: Streptococcus suis (S. suis) causes arthritis, meningitis, septicemia, and sudden death in pigs and is also
an zoonotic agent for humans. The present study demonstrated that immunization with recombinant Sao-L
(surface antigen one-L, rSao-L) protein from a strain of S. suis serotype 2 in pigs was able to increase cross-serotype
protection against S. suis serotype 1 and 2 challenge. Since weaning piglets are more susceptible to S. suis
infections due to the stresses associated with weaning, prepartum immunization in sows may convey passive
immunity to piglets and provide protection.
Results: Pregnant sows were immunized with a vaccine containing inactivated S. suis serotype 2 plus rSao as the
antigens. Blood samples were collected from their piglets after birth for analysis of antigen-specific antibody titers
and levels of various cytokines. Results demonstrated that the titers of S. suis and rSao-specific antibodies were
significantly (p < 0.05) higher in the vaccinated piglets in comparison with that of piglets in the control group. The
serum levels of interferon (IFN)-γ, interleukin (IL)-4, IL-6, and IL-12 were significantly (p < 0.05) increased in piglets
born from vaccinated sows when compared to piglets from unvaccinated sows. In addition, piglets were
challenged by heterologous and homologous S. suis. All piglets from unvaccinated sows developed severe
symptoms of bacteremia, fever, anorexia, depression, and arthritis. On the other hand, piglets from vaccinated sows
had significantly (p < 0.05) reduced clinical symptoms and lesion score (by 75 and 81%).
Conclusions: Our results revealed that immunizing pregnant sows with the vaccine containing inactivated S. suis
bacterin plus rSao as the antigens is able to enhance passive immunity against heterologous and homologous S.
suis challenge in their piglets.
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Background
Streptococcus suis (S. suis) causes a spectrum of diseases,
including arthritis, meningitis, septicaemia and sudden
death, in pigs and is recognized as an important zoonotic
agent for humans [1]. A total of 33 serotypes of S. suis, ac-
cording to the structure of its capsular polysaccharides
(CPS), have been identified [2]. Serotypes 1, 1/2, 2, 7, 9, 14
and 22 are more virulent than others and can be isolated
worldwide, including the United States, Canada, Europe,
and New Zealand [3]. In Taiwan, more than 80% of the
clinical cases are S. suis positive [4], and most of them are
infected with serotypes 1 and 2 [5]. The efficacy of many
commercially available inactivated S. suis whole-cell vac-
cines left something to be desired due to the fact that the
protection is only limited to homologous strains [6]. The
CPS has been shown to play a pivotal role in the patho-
genesis of S. suis, and that antibody against CPS (serotype
2) is essential for full protection from homologous
challenge [7]. CPS is a poor immunogen due to its
thymus-independent property and cannot induce suffi-
cient immune response [8]. Study showed that coupling S.
suis type 2 CPS to tetanus toxoid can induce T cell-
dependent response, inducing IgM and IgGs for protec-
tion against challenges in mice and pigs [9, 10]. In
addition, immunization with certain virulence factors,
such as suilysin, muramidase-released protein (MRP) and
extracellular factor (EF), has been demonstrated to protect
pigs from challenge with homologous or heterologous
strains of S. suis. However, discrepant results were re-
ported when different virulence factors are expressed by
the prevalent S. suis strains [11]. Therefore, researching
for a more immunogenic antigen that is commonly
expressed by most S. suis strains is imperative.
Many surface proteins are involved in the pathogenesis
of Gram-positive bacteria and have been shown to elicit
strong immune responses [12–14]. Immunization with
recombinant S. suis SsnA protein (surface-anchored
DNA-nuclease) formulated with aluminum hydroxide
was able to protect mice from S. suis infection [15]. A
new surface protein of S. suis, Abpb (amylase-binding
protein B) is recently identified and immunization with
recombinant Abpb provided effective protection against
S. suis [16]. In addition, a Lam protein (CDS0330) was
expressed on the cell surface of S. suis 2 and was found
to bind laminin in vitro. Immunization with recombin-
ant CDS 0330 protein resulted in 50% survival rate of
mice from S. suis 2 infection [17]. S. suis, Sao (surface
antigen one), a common surface protein containing an
Leu-Pro-X-Thr-Gly (LPXTG) motif, mediates many viru-
lence factors during the course of infection. Sao is highly
conserved among S. suis strains and has become a po-
tential antigen for the development of effective vaccines
against S. suis [13]. Sao protein is encoded by three
allelic variants of gene with different lengths, Sao-S
(1.5 kb), Sao-M (1.7 kb) and Sao-L (2.0 kb), respectively,
and Sao-M is the most prevalent variant [14].
Immunization with rSao protein was able to elicit strong
humoral antibody responses, decrease clinical signs and
bacterial dissemination, increase survival rates, and con-
fer cross-serotype protection in mouse and pig vaccin-
ation protocols [18], indicating that rSao is a suitable
antigen for subunit vaccine development.
We previously demonstrated that immunization with
recombinant Sao-L protein (rSao-L) from a strain of S.
suis serotype 2 in pigs was able to increase antigen-
specific antibody titers, the percentages of CD8+ and
CD4+/CD8+ double-positive T cells, and cross-protection
against S. suis serotype 1 heterologous challenge [19].
Since weaning piglets are more susceptible to S. suis infec-
tions due to the stress associated with weaning, prepartum
immunization in sows may convey passive immunity to
piglets and provide protection. This approach has been
proven effective in preventing common swine diseases
such as atrophic rhinitis [20], food-and-mouth disease
[21] and classical swine fever [22]. Moreover, immunizing
pregnant sows with a vaccine containing recombinant
Pasteurella multocida toxin (rsPMT) plus Pasteurella
multocida type A bacterin as the antigens significantly in-
creased neutralizing antibody titer in colostrum when
compared to pregnant sows immunized with the vaccine
containing rsPMT only [20]. The combination of recom-
binant antigens with inactivated bacteria may provide
extra antigens and elicit more broaden ranged protection
in immunized animals. In the present study, pregnant
sows were immunized with the vaccine containing inacti-
vated S. suis serotype 2 plus rSao-L as the antigens. Pas-
sive immunity in their piglets was analyzed by examining
serum antigen-specific antibody titers, levels of various cy-
tokines, including interferon (IFN)-γ, interleukin (IL)-4,
IL-6, IL-8, IL-12, and tumor necrosis factor (TNF)-α, and
clinical signs after heterologous and homologous chal-
lenges with S. suis serotype 1 and 2.
Methods
Bacterial strains and expression of rSao
S. suis serotype 1 and 2 strains were obtained from the
Pingtung County Animal Disease Control Center, Pingtung,
Taiwan. Bacteria were grown in brain-heart infusion (BHI)
broth supplemented with 0.5% yeast extract (Difco Labora-
tories, Spark, MD, USA) at 37 °C. The rSao was expressed
as previously described [19]. The size of PCR product from
the S. suis strain BCRC 14750 (ATCC 43765) was 2013 bp.
Primers for rSao gene were designed according to GenBank
accession no. JF 810176 (Sao-F: GCGGGAT CCATGAAT
ACTAAGAAATGGAG and Sao-R: CAGAA GCTTGAA
CTAATTTACGTTTACGTG). The primers contained re-
striction enzyme (Bam HI/Hind III) cutting sites and the
PCR product was cloned into the expression vector pET32a
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according to the manufacturer’s instructions (Novagen,
Darmstadt, Germany). E. coli strain BL21 (DE3) harboring
the recombinant plasmid was cultured in Luria-Bertanior
modified medium (tryptone: 6 g/L, soytone: 1.5 g/L, yeast
extract: 7.5 g/L, KH2PO4: 1.2 g/L, K2HPO4: 0.6 g/L, glucose:
2 g/L) at 37 °C until the absorbance reached 0.6 at 600 nm.
Isopropylthio-β-D-thiogalactose (IPTG) (Amresco, Ohio,
USA) was added at a final concentration of 1 mM, and the
culture was grown for 4 h with agitation. The resulting cul-
ture was ultrafiltrated by Vivaspin 20 100KDa MWCO (GE
Healthcare, UK). The concentrated culture was analyzed by
SDS-PAGE and Western blotting using the antisera from
rabbits immunized with purified rSao. Contamination of
endotoxin in the crude rSao was examined using Limulus
Amebocyte Lysate test, LAL (CAPE COD, MA, USA) and
the result was negative (no clotting, indicating that the con-
centration of endotoxin is less than 0.125 IU/mL).
Purification of rSao
E. coli expressing rSao were centrifuged at 4 °C, 14,000
xg for 20 min. The pellet was resuspended in denaturing
lysis buffer, sonicated using Misonix Sonicator S-4000
(Misonix, New York, USA), and filtered (0.22 μm). The
rSao was purified using the ProfiniaTM Protein Purifica-
tion System (BIO-RAD, California, USA) according to
the manufacturer’s instructions. Urea was incrementally di-
alyzed out of the samples, from 6 M, 5 M, 4 M, 3 M, 2 M,
and 1 M urea to 0.85% saline, using 12,000–14,000 MWCO
Dialysis Membrane (Cellu•Sep® MFPI,Orange Scientific,
Braine-l'Alleud, Belgium). Thereafter, BSA was used as the
standard for determining the concentration of rSao.
Preparation of vaccines
Formalin-inactivated S. suis serotype 2 bacteria and rSao
in the aqueous phase final concentration in the vaccine
for S. suis and rSao was 1x109 CFU/mL and 100 μg/mL,
respectively. The oil vaccine prepared with internal
aqueous phase was emulsified with 25% of water-in-oil-
in water (w/o/w) adjuvant containing two inactivated an-
tigens of S. suis and rSao: oil phase: external aqueous
phase ratios of 1:1:2 [19, 23]. The vaccine did not con-
tain any viable microorganisms, which was confirmed by
sterility test.
Immunization of pregnant sows
Ten healthy pregnant sows, without previous exposure
to S. suis (S. suis 2 antibody negative), were divided into
two groups (n = 5 each). The vaccinated group was intra-
muscularly immunized with S. suis serotype 2 plus rSao
vaccine (2 mL) 6 and 2 (boost) weeks before parturition.
The other group was injected with an equal volume of
sterile saline as the unvaccinated control. Animal experi-
ments were conducted in a private pig farm in Tainan
County, Taiwan, with informed consent from the owner
to conduct research. The pigs were selected and randomly
assigned to the treatment groups for the vaccine trial. All
experimental protocols for animal trials were approved by
the Animal Care and Use Committee, National Pingtung
University of Science and Technology (NPUST). The ex-
periments were conducted based on the Ethical Rules and
Law of NPUST.
Assessment of passive immunity in piglets
Blood samples (3–4 mL) were collected from the superior
vena cava 2, 4, and 6 weeks after parturition from 5 healthy
piglets randomly selected from each groups (n = 5) for de-
termining the serum antibody titer and cytokine levels. Five
weeks after parturition, 3 piglets were randomly selected
from each group (n = 3) and challenged i.p. with 2 mL
(1.06 × 109 CFU/mL) of live S. suis serotype 1 (P1) or S.
suis serotype 2 (P2) bacteria. The piglets were monitored
daily for clinical signs, body temperature (fever was defined
as anal temperature≧40 °C), and bacteremia. Seven days
after the challenge, the piglets were i.m. injected with
Stresnil (0.1 mL/kg), sacrificed, and dissected. Thereafter,
pathological examination was performed and lesion score
was calculated based on the area of lesions in an organ,
where no lesion = 0, lesion area < 33% = 1, lesion area
33–66% = 3, lesion area > 66% = 5. The necropsy samples
of various organs were cultured for bacteriological analysis.
Indirect enzyme-linked immunosorbent assay (ELISA) for
serum antibody titers
Flat-bottomed 96-well plates were coated with either S.
suis serotype 2 bacteria (1.25 μg/mL) or purified rSao
(1.25 μg/mL) in the coating buffer (15 mM Na2CO3,
35 mM NaHCO3, 3 mM NaN3, pH = 9.6) at 4 °C over-
night. The serum antibody titers were determined as
described [19], where S/P ratio = (Sample – NCˉ x) /
(PCˉ x – NCˉ x) (NC: negative control, PC: positive
control). To obtain positive serum, S. suis-negative
SPF pigs were challenged with 2 ml (1 × 109 CFU/ml)
S. suis 2 and serum was collected 14 days later.
Detection of serum cytokine levels
The serum cytokine levels, including IFN-γ, TNF-α, IL-
4, IL-6, IL-8 and IL-12, were analyzed using the MILL-
PLEX® MAP Kit (EMD Millipore Corporation, Billerica,
MA, USA) according to the manufacturer’s instructions.
The plates were read by MAGPIX® plate reader at 470–
565 nm (EMD Millipore Corporation).
Detection of bacteremia by multiplex PCR
The detection of bacteremia in blood and organ samples
after challenge was carried out using bacteriology and the
Multiplex PCR based method. Primers for S. suis cps II
and Sao gene were designed by Smith [24] and Hsueh
[19], respectively: (cps II-F: GGCGGTCTAGCAGATGC
Hsueh et al. BMC Veterinary Research  (2017) 13:15 Page 3 of 9
TCG and cps II-R: GCGAACTGTTAGCAATGAC)
(Sao-F: GCGGGATCCATGAATACTAAGAAATGGAG
and Sao-R: CAGAAGCTTGAACTAATTTACGTTTAC
GTG). Bacterial DNA was isolated using the Blood &
Tissue Genomic DNA extraction Miniprep System kit
(Viogene, Sunnyvale, CA, USA). The genes were amplified
by 30 PCR cycles consisting of 1 min denature at 94 °C,
2 min annealing at 56 °C and 2 min elongation at 72 °C.
Statistical analysis
All data were expressed as mean ± S.E.M. and were com-
pared using Student’s t-test. A p-value of < 0.05 was con-
sidered significant.
Results
Incidence of fever and bacteremia after challenge
Two piglets from the control group had fever on the
first (≧40 °C) and second (≧41 °C) day after challenge.
One of the piglets with fever was confirmed to have
bacteremia and died on the third day after challenge. In
contrast, all piglets from the vaccinated group remained
healthy and no fever was observed (Table 1). Results of
multiplex PCR demonstrated that all the piglets in the
control group had bacteremia during the first two days
after challenge (Fig. 1). On the other hand, only one piglet
in the vaccination group had bacteremia on the second
day (Table 1) and seventh day (Table 2) after challenge.
The difference between the vaccinated and the control
group was marginal significant (P = 0.058 and P = 0.140)
(Tables 1 and 2).
Serum antigen-specific antibody titers
Results indicated that antigen-specific antibodies, IgG
against S. suis serotype 2 bacteria and rSao, in serum
were significantly (P < 0.05) increased in piglets born
from vaccinated sows in comparison with those in pig-
lets born from the unvaccinated sows at 2, 4, and 6 weeks
after parturition (Fig. 2a and b). The titer of serum IgG
against S. suis 2, but not rSao, was remarkably reduced
for piglets 6 weeks of age.
Serum cytokine levels
The concentration of IFN-γ in serum was significantly
(P < 0.05) increased in the piglets from vaccinated sows
at 2 and 4 weeks of age when compared to that of piglets
from unvaccinated sows (Fig. 3a). Whereas the concen-
trations of IL-4 (Fig. 3b), IL-6 (Fig. 3c), and IL-12
(Fig. 3d) were significantly (P < 0.05) elevated in piglets
from vaccinated sows at 2, 4, and 6 weeks after partur-
ition when compared to those of piglets from unvaccin-
ated sows. In contrast, piglets from vaccinated sows had
a significantly (P < 0.05) higher concentration of IL-8 at
2, but not 4 and 6 weeks of age (Fig. 3e), when com-
pared to piglets from vaccinated sows. In the case of
TNF-α, no differences were observed between the two
groups at all the time points (Fig. 3f ).
Table 1 Fever and bacteremia of piglets after challenge with
heterologous Streptococcus suis serotype 1 bacteria
Groupa Cases of fever/ bacteremiab (%)
Day 0 1 2 3 4 5 6 7
Vaccinationc 0/0 0/0 0/33 0/0 0/0 0/0 0/0 0/0
Control 0/0 33 d/100 33 e/100 0/0 f 0/0 0/0 0/0 0/0
aVaccination: S. suis 2 + rSao, Control: sterile saline
bThe fever and bacteremia of piglets were monitored daily for 7 days
after challenge
cDifferences between groups were analyzed by Student’s t-test P = 0.0584
dBody Temperature≧40 °C,e Body Temperature≧41 °C
fOne death occurred on the third day after challenge. The presence of S.
suis serotype
1 bacteria was confirmed by bacteriology and multiplex PCR
Fig. 1 Detection of Sao and cps II genes in bacteremia samples by multiplex PCR. M: 100 bp DNA Ladder; Lane 1–6: n of 3 on day 1 and 2 after
challenge as control group; Lane 7: Vaccinated group, two days after challenge; Lane 8: S. suis serotype 1 as the positive control
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Clinical symptoms and pathological lesions after sacrifice
According to the pathological examination, piglets from
sows in the control group showed various clinical signs,
including fever, anorexia, and gross lesions in the peri-
toneal cavity, joints and lungs, in response to the chal-
lenge. In contrast, piglets from sows in the vaccinated
group remained healthy and only mild lesions were
observed. Results from the lesion score indicated that
prepartum vaccination in sows significantly (P < 0.05) re-
duced the lesion score by 75% (7 v.s. 27) and 81% (4 v.s.
21) in their piglets after challenge with S. suis serotype 1
and 2 bacteria, respectively (Tables 3 and 4). Presence of
S. suis bacteria in the necropsy samples of various or-
gans (synovial fluid, peritoneal cavity and lungs) was
verified and confirmed, using multiplex PCR, to be
the S. suis serotype 1 and 2 strains used for challenge
(Tables 1 and 2).
Histopathological examination
All piglets survived from challenge were sacrificed and
dissected on the 7th day after challenge. Thereafter,
histopathological examination was performed. Piglets
from unvaccinated sows displayed signs of lesions in the
brain and lung, including slight vascular congestion on
the brain meninges, influx of neutrophils, lymphocytes,
and shedded epithelial cells in the lung alveolar space,
and accumulation of neutrophils in the bronchium cav-
ity, indicating the development of bronchopneumonia,
hemorrhagic bronchial pneumonia, and lung abscess
(Fig. 4a and b). In contrast, above-mentioned signs of
Table 2 Fever and bacteremia of pig after challenge with
homologous Streptococcus suis serotype 2 bacteria
Groupa Cases of fever / bacteremiab (%)
Day 0 1 2 3 4 5 6 7
Vaccinationc 0/0 33/0 0/0 0/0 33/0 0/0 0/0 0/0
Control 0/0 33d/0 33 /0 0/0 0/0 0/0 0/0 0/33
aVaccination: S. suis 2 + rSao, Control: sterile saline
bThe fever and bacteremia of piglets were monitored daily for 7 days
after challenge
cDifferences between groups were analyzed by Student’s t-test P = 0.140
dBody Temperature≧40 °C
Fig. 2 The antibody response of (a) S. suis 2 (b) rSao-specific IgG in the serum of piglets from sows with or without (n = 5 each) prepartum
immunization with inactivated S. suis 2 + rSao. Data are represented as Mean ± SEM of peak absorbance values as determined by indirect ELISA
performed on diluted (1:500) serum samples. S/P ratio = (sample – Nˉx) / (PCˉx – NCˉx). Differences between groups were analyzed by Student’s
t-test, statistically significant difference (P < 0.05) in comparison to the control group
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lesions were not observed in piglets from vaccinated
sows after dissection.
Discussion
Piglets are more susceptible to infections due to the stress
associated with weaning and the immature immune system
during the early stage of life. Prepartum immunization in
sows has been proven safe and efficiently conveys protec-
tion to piglets through the transfer of passive immunity in
milk. Prepartum vaccination with a subunit vaccine con-
taining recombinant Pasteurella multocida toxin proteins
as the antigen in sows was able to enhance the level of neu-
tralizing antibodies, reduce the degree of turbinate atrophy,
and increase the survival rate in piglets with experimentally
induced progressive atrophic rhinitis (PAR) [20]. Immuniz-
ing pregnant sows (52 and 32 days before parturition, re-
spectively) with a type O1 foot and mouth disease oil
emulsion vaccine significantly increased the serum level of
neutralizing antibodies in piglets 3 days after birth [21].
Moreover, 3-week-old piglets born from sows immunized
with a classical swine fever vaccine (E2) twice after insem-
ination had significantly higher maternal antigen-specific
antibodies as indicated by the ND50 (neutralization dilution
50%) [22].
We previously demonstrated that immunization with
the rSao (from serotype 2 S. suis) protein expressed by
bioreactors formulated with w/o/w adjuvant increased
antigen-specific antibody titers, the percentages of CD8+
and CD4+/CD8+ double-positive T cells, and successfully
provided cross-serotype protection against the challenge
of heterologous S. suis serotype 1 bacteria in pigs [19].
In combination with Quil A, rSao can reduce clinical
symptoms after challenge infection with heterologous S.
suis and stimulates strong opsonizing antibody responses
[18]. A previous study has indicated that the pregnant
sows immunized with a PAR vaccine containing three
short fragments of recombinant subunit Pasteurella
multocida toxin (rsPMT) in combination with Pasteur-
ella multocida type A bacterin (rsPMT + P. multocida
bacterin) as the antigens can elicit higher neutralizing
antibody titer in colostrum than pregnant sows immu-
nized with the vaccine containing rsPMT only (1:101 v.s.
1:80) [20]. The immunization protected 60% of piglets
born from these sows after challenged by intramuscular
injection with five-fold lethal dose of authentic PMT.
The results implied that combination of recombinant
antigen with inactivated bacteria as the antigen may en-
hance the immune responses elicited by the vaccine. In
Fig. 3 The concentration of cytokine (a) IFN-γ (b) IL-4 (c) IL-6 (d) IL-12 (e) IL-8 (f) TNF-α in piglets from sows with or without (n = 5 each) prepartum
immunization with inactivated S. suis 2 + rSao. Data are represented as Mean ± SEM of the serum concentration of each cytokines determined by
MILLPLEX® MAP Kit. Differences between groups were analyzed by Student’s t-test, statistically significant difference (P < 0.05) in comparison to the
control group





The Score of Gross Lesionsb
Brain Serosa Joint Spleen Liver Lung
Vaccination 7 75%c 1 (1/3) 0 (0/3) 3 (1/3) 0 (0/3) 0 (0/3) 3 (1/3)
Controld 27 - 1 (1/3) 7 (3/3) 7 (3/3) 1 (1/3) 4 (2/3) 7 (3/3)
aVaccination: S. suis2 + rSao, Control: sterile saline
bNo lesion = 0, lesion area <33% = 1, lesion area 33–66% = 3, lesion area >66% = 5
cDifferences between groups were analyzed by Student’s t-test P < 0.05
dThe number of piglets in a group that was confirmed to have the presence of S
suis serotype 1 bacteria
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addition, virulence factors of S. suis other than Sao, such
as suilysin, muramidase-released protein (MRP), and
extracellular factor (EF), also play a role in the pathogen-
esis of S. suis. Immunization with a subunit vaccine con-
taining these virulence factors (MRP+/EF+) from S. suis
serotype 2 as the antigens has been demonstrated to
protect pigs from challenge of homologous or heterol-
ogous S. suis strains [25]. Addition of inactivated S. suis
bacteria containing these surface virulent factors into
the vaccine formula may provide extra antigens and
elicit broader protection in immunized animals. There-
fore, pregnant sows were immunized with the vaccine
containing inactivated S. suis serotype 2 plus rSao as the
antigens and the passive immunity against heterologous
S. suis serotype 1 infection in their piglets was investi-
gated in the present study.
The serum titer of IgG against rSao and S. suis sero-
type 2 in piglets from vaccinated sows remained signifi-
cantly higher than that of piglets from unvaccinated sow
until 6 weeks of age (Fig. 2a and b). After challenge with
live S. suis serotype 1 bacteria, the lesion score of piglets
from vaccinated sows was reduced by 75%. These results
implied that immunization with rSao plus inactivated S.
suis serotype 2 in pregnant sows enhanced the passive
immunity against S. suis and provided cross-protection
in their piglets. The Sao protein is highly conserved
among S. suis strains and Sao-specific antibodies have
been shown to cross-react with 28 different serotypes of
S. suis [13]. The lesion score was reduced by 60% in pigs
immunization with rSao alone after challenge with live
heterologous S. suis bacteria [19]. Results from the
present study revealed that the lesion score was reduced
by 75% in piglets born from sows immunized with inac-
tivated S. suis bacteria plus rSao after challenge with live
heterologous S. suis bacteria.
In piglets produced by vaccinated sows, the antigen-
specific IgG titer remained high until 6 weeks of age
(Fig. 2a and b). This is in agreement with a previous
study in which pregnant sows were immunized with the
autogenous S. suis bacterin and MRP-specific IgG
remained detectable until 6 weeks of age [25]. However,
a remarkable reduction of the antigen-specific IgG titer
in serum was observed in the 6 weeks of age in compari-
son with the titers in the 2 and 4 weeks of age, which is
possibly due to the half-life of IgG absorbed from colos-
trum. The IgG concentrations in piglets at 24 h of age





The Score of Gross Lesionsb
Brain Serosa Joint Spleen Liver Lung
Vaccination 4 81.0%e 0 (0/3) 0 (0/3) 0 (0/3) 0 (0/3) 0 (0/3) 4 (2/3)
Controld 21 - 0 (0/3) 0 (0/3) 0 (0/3) 5 (3/3) 3 (3/3) 13 (3/3)
aVaccination: S. suis2 + rSao, Control: sterile saline
bNo lesion = 0, lesion area <33% = 1, lesion area 33– 66% = 3, lesion area >66% = 5
cDifferences between groups were analyzed by Student’s t-test P < 0.05
dThe number of piglets in a group that was confirmed to have the presence of S
suis serotype 2 bacteria
a b
Fig. 4 Results of histopathological examination. Piglets from sows with or without prepartum immunization with inactivated S. suis 2 + rSao were
challenged with (a) heterologous S. sui serotype 1 and (b) homologous S. sui serotype 2 bacteria at the 5 weeks of age. The histopathological
examination was performed on the 7th day after the challenge. Control pigs manifested severe brain and lung lesions, including slight vascular
congestion on the brain meninges and shedded epithelial cells in the lung alveolar space
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ranged from 18.7 to 39 mg/mL and gradually decreased
to 6.3 mg/mL at 5 to 6 weeks of age [26]. The w/o/w
adjuvant used in our vaccine has been shown to stimu-
late both humoral and cell-mediated arms of immune
responses [17, 23].
Compared to piglets from sows in the control group,
piglets from sows in the vaccinated group had signifi-
cantly (P < 0.05) increased levels of IL-4, IL-6, IL-12, and
IFN-γ in serum after parturition. The source of these cy-
tokines in piglets’ circulation could be mainly from the
absorption of cytokines in colostrum before gut closure.
IL-4 and IL-6 plays a role in enhancing Th2-type immune
responses, B cell proliferation, and antibody production
[27]. On the other hand, IL-12 and IFN-γ are the key cyto-
kines that lead immune responses to Th1-type. IL-12 acti-
vates immune cells, such as NK cells and naïve CD4+ T
cells, to secret IFN-γ, which in turn facilitate macrophages
maturation [28–32]. Therefore, the higher concentration
of cytokines in serum may contribute, at least partially, to
the enhanced resistance to challenge with live S. suis bac-
teria in piglets from vaccinated sows. It is unclear why the
level of serum IL-8 was increased only at 2 weeks after
parturition in piglets from sows in the control group. IL-8
is a potential chemoattractant that is up regulated during
the course of intramammary infections [33]. However,
whether the sows had mastitis was not determined in our
study. The serum levels of TNF-α were low and not differ-
ent between the two groups, which is probably due to the
short half-life of this cytokine [27].
Results of the histopathological examination revealed
that piglets from unvaccinated sows had slight vascular
congestion on the brain meninges, influx of neutrophils,
lymphocytes, and shedded epithelial cells in the lung al-
veolar space, and signs of suppurative bronchopneumo-
nia, hemorrhagic bronchial pneumonia, and lung abscess
(Fig. 4a and b). In piglets i.v. challenged by live S. suis,
the main lesions (found in the joints, spleen, liver, and
kidneys) are associated with synovitis, spleen inflamma-
tion, hepatitis, and pneumonia [25]. Dissection of the
piglet that died on the third day after challenge showed
severe lesions in the lung. In contrast, lesions were not
found in any of the piglets from sows in the vaccinated
group after dissection, indicating that the enhanced pas-
sive immunity against S. suis was sufficient to protect
piglets from S. suis challenge.
Conclusions
Prepartum immunization of inactivated S. suis bacterin
plus rSao in sows was able to increase serum antigen-
specific antibody titers, the concentrations of IFN-γ, IL-
4, IL-6 and IL-12 in serum, and provide cross-protection
against S. suis infections in the piglets. The protection
was characterized by the reduction on lesion score (75
and 81%), bacteremia, and fever. This vaccine and
immunization approach may be applied to enhance the
protection against both heterologous and homologous S.
suis infections in newborn piglets.
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